IL18BP and sarcopenia: Therefore, to determine whether the same would be true in patients with clinically relevant, chronic sarcopenia, we quantified IL-18BP in the plasma of patients enrolled in the LACE clinical trial by ELISA and compared it with physical performance at baseline, and after 6 and 12 months of the trial.